Moderna COVID-19 vaccine 94.5% effective at preventing COVID-19


  • Heather Mason
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

The European Medicines Agency (EMA) has started a rolling review of Moderna's mRNA-1273 COVID-19 vaccine, after the company reported interim data from the clinical trial.

Preliminary results from non-clinical studies and early clinical studies in adults suggest the vaccine triggers the production of antibodies and T cells.

The primary endpoint of the clinical study was based on the analysis of confirmed COVID-19 cases, adjudicated starting two weeks following the second dose of the mRNA-1273 vaccine. There were 95 confirmed case of COVID-19, of which 90 were observed in the placebo group versus five in the vaccine group.

The phase 3 study met statistical criteria, with vaccine efficacy of 94.5 per cent. The 95 COVID-19 cases included 15 older adults (ages 65+) and 20 participants identifying as being from diverse communities.

A secondary endpoint was severity of COVID-19. Eleven severe cases (as defined in the study protocol) were reported in this first interim analysis. All 11 cases occurred in the placebo group, and none in the mRNA-1273 vaccinated group.

The safety analysis showed that the majority of adverse events were mild or moderate in severity, and the preliminary analysis suggests a broadly consistent safety and efficacy profile across all evaluated subgroups.